Jump to Navigation

Gabitril Fact Sheet

Printer-friendly version
Medication Name (brand): 
Gabitril
Medication Name (clinical): 
tiagabine
Manufacturer: 

Cephalon

Indications: 
  • Adjunctive treatment of epilepsy.

  • A small amount of evidence for efficacy in anxiety; used sometimes for substance abusers as a non-addictive alternative to benzos, but evidence of efficacy for this is lacking.

Mechanism: 

GABA Reuptake Inhibitor

Dosing: 
  • Supplied in 2 mg, 4 mg, 12 mg, and 16 mg tablets.

  • Dosing recommendations in PDR are applicable to epileptic patients already on other anti-seizure meds that induce Gabitril’s metabolism, so these are not applicable to typical psychiatric dosing.
  • In psychiatry, anecdotal reports suggest starting at 2 mg BID and increasing by 2 mg increments as needed. Max recommended PDR dose is 32 mg QD.
  • No dose adjustment required for elderly or in renal impairment. Reduce dose in patients with hepatic impairment.

Side Effects: 
  • Most common are dizziness, sedation, jitteriness, tremor, and impaired memory/concentration.

  • Postmarketing reports have shown that Gabitril can induce seizures in patients with no history of epilepsy, although this is rare.

Drug-drug Interactions: 

Metabolized by CYP 3A and several other enzymes. Enzyme inducers such as Tegretol (carbamazepine) may decrease Gabitril levels.

Pearls: 
  • High fat meals decrease rate of absorption.

  • Half-life 7-9 hours.

Return to issue area